Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced data showcasing its proprietary INTASYL platform and compounds. INTASYL offers precise targeting by silencing mRNA both intracellularly and extracellularly, enhancing immune responses against cancer. The technology is effective as intratumoral injections and during immune cell expansion for adoptive cell therapy, requiring no special formulations for siRNA delivery.
Key INTASYL compounds include:
- PH-762: Silences PD-1, improving therapeutic efficacy in vivo
- PH-894: Silences BRD4, enhancing tumor cell immunogenicity and inducing apoptosis
- PH-804: Silences TIGIT in NK cells, enhancing activation, cytokine release, and target cell killing
- PH-905: Silences CBLB, increasing NK cell cytotoxicity and proliferation
The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) ha annunciato dati che mostrano la sua piattaforma proprietaria INTASYL e i suoi composti. INTASYL offre un targeting preciso silenziando l'mRNA sia intracellularmente che extracellularmente, migliorando le risposte immunitarie contro il cancro. La tecnologia è efficace sia come iniezioni intratumorali che durante l'espansione delle cellule immunitarie per la terapia con cellule adottive, senza richiedere formulazioni speciali per la somministrazione di siRNA.
I principali composti di INTASYL includono:
- PH-762: Silenzia PD-1, migliorando l'efficacia terapeutica in vivo
- PH-894: Silenzia BRD4, aumentando l'immunogenicità delle cellule tumorali e inducendo l'apoptosi
- PH-804: Silenzia TIGIT nelle cellule NK, potenziando l'attivazione, il rilascio di citochine e l'eliminazione delle cellule bersaglio
- PH-905: Silenzia CBLB, aumentando la citotossicità e la proliferazione delle cellule NK
I dati saranno presentati al 20° Congresso Annuale della Oligonucleotide Therapeutics Society (OTS) a Montreal l'8 ottobre.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) anunció datos que muestran su plataforma propietaria INTASYL y sus compuestos. INTASYL ofrece un direccionamiento preciso al silenciar el mRNA tanto intracelular como extracelularmente, mejorando las respuestas inmunitarias contra el cáncer. La tecnología es efectiva como inyecciones intratumorales y durante la expansión de células inmunitarias para la terapia celular adoptiva, sin requerir formulaciones especiales para la entrega de siRNA.
Los compuestos clave de INTASYL incluyen:
- PH-762: Silencia PD-1, mejorando la eficacia terapéutica in vivo
- PH-894: Silencia BRD4, mejorando la inmunogenicidad de las células tumorales e induciendo apoptosis
- PH-804: Silencia TIGIT en células NK, mejorando la activación, la liberación de citoquinas y la eliminación de células blanco
- PH-905: Silencia CBLB, aumentando la citotoxicidad y proliferación de las células NK
Los datos se presentarán en la 20ª Reunión Anual de la Sociedad de Terapias con Oligonucleótidos (OTS) en Montreal el 8 de octubre.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO)는 자사의 독점 INTASYL 플랫폼 및 화합물에 대한 데이터를 발표했습니다. INTASYL은 세포내 및 세포외에서 mRNA를 침묵시켜 암에 대한 면역 반응을 강화하여 정밀 타겟팅을 제공합니다. 이 기술은 종양 내 주사 및 세포 치료를 위한 면역 세포 확장 중에 효과적이며 siRNA 전달을 위해 특별한 제형이 필요하지 않습니다.
주요 INTASYL 화합물은 다음과 같습니다:
- PH-762: PD-1을 침묵시켜 생체 내 치료 효과를 개선합니다
- PH-894: BRD4를 침묵시켜 종양 세포의 면역원성을 향상시키고 세포 자멸사를 유도합니다
- PH-804: NK 세포에서 TIGIT을 침묵시켜 활성화, 사이토카인 방출 및 표적 세포 사멸을 증가시킵니다
- PH-905: CBLB를 침묵시켜 NK 세포의 세포 독성과 증식을 증가시킵니다
이 데이터는 10월 8일 몬트리올에서 열리는 제20회 연례 올리고뉴클레오타이드 치료학회(OTS)에서 발표될 예정입니다.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) a annoncé des données démontrant sa plateforme propriétaire INTASYL et ses composés. INTASYL offre un ciblage précis en silence l'ARNm à la fois intracellulairement et extracellulairement, améliorant ainsi les réponses immunitaires contre le cancer. La technologie est efficace en tant qu'injections intratumorales et lors de l'expansion des cellules immunitaires pour la thérapie par cellules adoptives, sans nécessiter de formulations spéciales pour la livraison de siRNA.
Les principaux composés d'INTASYL incluent :
- PH-762: Silencie PD-1, améliorant l'efficacité thérapeutique in vivo
- PH-894: Silencie BRD4, augmentant l'immunogénicité des cellules tumorales et induisant l'apoptose
- PH-804: Silencie TIGIT dans les cellules NK, améliorant l'activation, la libération de cytokines et l'élimination des cellules cibles
- PH-905: Silencie CBLB, augmentant la cytotoxicité et la prolifération des cellules NK
Les données seront présentées lors de la 20e Réunion annuelle de la Société des thérapies par oligonucléotides (OTS) à Montréal le 8 octobre.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) hat Daten vorgestellt, die ihre eigene INTASYL-Plattform und deren Verbindungen zeigen. INTASYL bietet präzise Zielansteuerung, indem es mRNA sowohl intrazellulär als auch extrazellulär zum Schweigen bringt und so die Immunantworten gegen Krebs verbessert. Die Technologie ist wirksam als intratumorale Injektionen und während der Erweiterung von Immunzellen für die adoptive Zelltherapie und benötigt keine speziellen Formulierungen für die siRNA-Zufuhr.
Wichtige INTASYL-Verbindungen umfassen:
- PH-762: Schweigt PD-1 und verbessert die therapeutische Wirksamkeit in vivo
- PH-894: Schweigt BRD4, verbessert die Immunogenität von Tumorzellen und induziert Apoptose
- PH-804: Schweigt TIGIT in NK-Zellen, erhöht die Aktivierung, den Cytokinfreisetzung und das Abtöten von Zielzellen
- PH-905: Schweigt CBLB und erhöht die Zytotoxizität und Proliferation von NK-Zellen
Die Daten werden am 8. Oktober auf der 20. Jahrestagung der Oligonucleotide Therapeutics Society (OTS) in Montreal präsentiert.
- INTASYL platform enhances immune responses against cancer
- Technology effective as intratumoral injections and for adoptive cell therapy
- No special formulations required for siRNA delivery
- Multiple compounds targeting different pathways in cancer immunotherapy
- None.
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T
Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its proprietary INTASYL platform and INTASYL compounds.
INTASYL compounds offer precise targeting by silencing mRNA both intracellularly and extracellularly, significantly enhancing immune responses against cancer. They are effective as intratumoral injections and as excipients during immune cell expansion for adoptive cell therapy. INTASYL's efficient delivery system requires no special formulations to streamline siRNA delivery to target cells.
INTASYL compound PH-762 silences PD-1, improving therapeutic efficacy in vivo. The PH-894 compound precisely silences BRD4 to enhance tumor cell immunogenicity and induce apoptosis. Silencing TIGIT in NK cells, using compound PH-804, enhances their activation, cytokine release, and target cell killing. The PH-905 compound silences CBLB, increasing NK cell cytotoxicity and proliferation.
The data is being presented on October 8th at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225579
FAQ
What is the main focus of Phio Pharmaceuticals' INTASYL technology?
How many INTASYL compounds did Phio Pharmaceuticals (PHIO) present data on?
When and where will Phio Pharmaceuticals (PHIO) present its INTASYL data?
What are the advantages of Phio Pharmaceuticals' (PHIO) INTASYL delivery system?
